AIM: To study the expression of the inhibitor of apoptosis protein survivin in hepatocellular carcinoma (HCC), and its correlation with clinicopathological factors, cell proliferation, recurrence and prognosis after hepatectomy. METHODS: Immunohistochemical staining of survivin and Ki-67 was performed by the standard streptavidin-peroxidase technique on paraffin sections of 55 cases of HCC. RESULTS: The positive rate of survivin in HCC was 52.7% (29/55). Significant correlation was found between survivin expression with portal vein thrombi and intrahepatic matastasistic nodes (P < 0.05). The recurrent rate in survivin-positive HCC was significantly higher than that in survivin-negative HCC after hepatectomy, the 1- and 3-year survival rate in patients with survivin-positive tumors was significantly lower than that in patients with survivin-negative tumors (58.62 and 10.34% vs 76.92 and 30.77%, P < 0.05, log-rank test). The proliferation index (Ki-67) in survivin-positive HCC (33.83% +/- 18.90%) was significantly higher than that in survivin-negative HCC (19.60% +/- 19.35%) (P < 0.05). CONCLUSION: Survivin may play an important role in progression of HCC by promoting cell proliferation, and may be positively correlated with high risk of disease recurrence and poor prognosis in HCC. Its expression may serve as a prognostic factor for patients with HCC after hepatectomy.
AIM: To study the expression of the inhibitor of apoptosis protein survivin in hepatocellular carcinoma (HCC), and its correlation with clinicopathological factors, cell proliferation, recurrence and prognosis after hepatectomy. METHODS: Immunohistochemical staining of survivin and Ki-67 was performed by the standard streptavidin-peroxidase technique on paraffin sections of 55 cases of HCC. RESULTS: The positive rate of survivin in HCC was 52.7% (29/55). Significant correlation was found between survivin expression with portal vein thrombi and intrahepatic matastasistic nodes (P < 0.05). The recurrent rate in survivin-positive HCC was significantly higher than that in survivin-negative HCC after hepatectomy, the 1- and 3-year survival rate in patients with survivin-positive tumors was significantly lower than that in patients with survivin-negative tumors (58.62 and 10.34% vs 76.92 and 30.77%, P < 0.05, log-rank test). The proliferation index (Ki-67) in survivin-positive HCC (33.83% +/- 18.90%) was significantly higher than that in survivin-negative HCC (19.60% +/- 19.35%) (P < 0.05). CONCLUSION: Survivin may play an important role in progression of HCC by promoting cell proliferation, and may be positively correlated with high risk of disease recurrence and poor prognosis in HCC. Its expression may serve as a prognostic factor for patients with HCC after hepatectomy.
Authors: Paul N Span; Vivianne C G Tjan-Heijnen; Joop J T M Heuvel; Jacques B de Kok; John A Foekens; Fred C G J Sweep Journal: Clin Chem Date: 2006-07-27 Impact factor: 8.327
Authors: Whitney Salz; Dan Eisenberg; Janet Plescia; David S Garlick; Robert M Weiss; Xue-Ru Wu; Tung-Tien Sun; Dario C Altieri Journal: Cancer Res Date: 2005-05-01 Impact factor: 12.701
Authors: T Ito; K Shiraki; K Sugimoto; T Yamanaka; K Fujikawa; M Ito; K Takase; M Moriyama; H Kawano; M Hayashida; T Nakano; A Suzuki Journal: Hepatology Date: 2000-05 Impact factor: 17.425
Authors: Meiling Lu; Toni Kwan; Chunjiang Yu; Feng Chen; Bethany Freedman; Jennifer M Schafer; Eun-Jig Lee; J Larry Jameson; V Craig Jordan; Vincent L Cryns Journal: J Biol Chem Date: 2004-11-29 Impact factor: 5.157
Authors: D S O'Connor; D Grossman; J Plescia; F Li; H Zhang; A Villa; S Tognin; P C Marchisio; D C Altieri Journal: Proc Natl Acad Sci U S A Date: 2000-11-21 Impact factor: 11.205
Authors: B M Ryan; G E Konecny; S Kahlert; H-J Wang; M Untch; G Meng; M D Pegram; K C Podratz; J Crown; D J Slamon; M J Duffy Journal: Ann Oncol Date: 2006-01-10 Impact factor: 32.976
Authors: Jenilyn J Virrey; Shengxi Guan; Wei Li; Axel H Schönthal; Thomas C Chen; Florence M Hofman Journal: Am J Pathol Date: 2008-07-03 Impact factor: 4.307